The phase I clinical study about the combined therapy, high purity natural killer (NK) cell therapy and IgG1 antibody to inoperable advance and recurrence digestive cancer
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2018
Price : $35 *
At a glance
- Drugs Natural killer cell therapy-Takara-Bio (Primary) ; Cetuximab; Immunoglobulin G; Trastuzumab
- Indications Colon cancer; Colorectal cancer; Gastric cancer
- Focus Adverse reactions
- 10 Sep 2018 Status changed from recruiting to completed.
- 09 Sep 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 29 Jul 2014 New trial record